Revealing the BRD4-NOTCH3 fusion: a novel hill in the cancer landscape

Transcript fusions have long been associated with cancer development. The recent use of comprehensive DNA/RNA sequencing in the cancer scenario has uncovered fusions that, today, are seen as optimal targets for personalized medicine, such as those involving genes ALK, FGFR and NTRK [1]. The most frequent cancer driver fusions emerged from data cohorts such as TCGA consortium [1]. However, rare driver fusions can only be observed using extremely large cohorts, remaining as potential targets to be explored [2].

Source: Lung Cancer - February 17, 2021 Category: Cancer & Oncology Authors: Fabiano de Almeida Costa, Mariane Tami Amano, Paula Fontes Asprino, Dean C. Pavlick, Cibele Masotti, Leonardo Testagrossa, Gilberto de Castro Source Type: research